Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
Investing.com - Raymond (NSE:RYMD) James reiterated its Outperform rating and $340 price target on Humana (NYSE:HUM), currently trading at $245.68, following the company’s second-quarter 2025 results that exceeded expectations. According to InvestingPro data, 13 analysts have recently revised their earnings estimates upward for the upcoming period.
Humana reported adjusted earnings per share of $6.27, surpassing the Street consensus of $5.92 and Raymond James’ estimate of $5.69. The company’s insurance medical loss ratio came in at 89.9%, in line with Street expectations and slightly better than Raymond James’ forecast of 90.0%.
Management raised its 2025 EPS guidance by $1.00 to $17.00, despite including $100 million in incremental investment spending for Stars ratings and back office technology improvements. Without this increased spending, the 2025 EPS guidance would have been approximately $17.60.
Raymond James noted that Humana appears to be reinvesting upside into initiatives that will drive longer-term value, particularly to recapture approximately $2.2 billion in Stars program revenue and achieve other operational efficiencies.
The investment firm increased its 2026 EPS estimate to $11.00 (up $1.00) and its 2027 estimate to $21.00 (up $0.71), while maintaining its 2028 estimate at $40.00. Raymond James views Humana as a relatively inexpensive way to invest in the Medicare Advantage recovery, trading at approximately 6x P/E on 2028 estimated EPS with mature margins, compared to UnitedHealth (NYSE:UNH)’s multiple of around 10x.
In other recent news, Humana Inc . reported impressive financial results for the second quarter of 2025. The company achieved an earnings per share (EPS) of $6.27, surpassing analysts’ expectations of $5.87. Additionally, Humana exceeded revenue projections with $32.39 billion, compared to the anticipated $31.85 billion. These results highlight Humana’s strong performance and have likely contributed to increased investor confidence. While stock price movement was notable, it is not the focus here. This development is part of a series of recent updates concerning Humana. Investors will be closely monitoring any further announcements from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.